Skip to main content
psoriatic.PIP_.JPG

Biologic Persistence in Psoriatic Arthritis and Psoriasis

May 19, 2022

Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.

Read Article
SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

May 18, 2022

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
FDA.Safety.jpg

Bimekizumab Development Delayed by FDA

May 16, 2022

UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).

Read Article
Bimekizumab's Favorable Safety Profile in Psoriasis A 2-year safety study of BMK, the dual IL-17A/F inhibitor, plaque psoriasis patients showed BMK, to be effective, well tolerated, w/ no new safety concerns other than a modest risk of oral candidiasis.https://t.co/84zS8VET6B https://t.co/aLvLmmTc93
Dr. John Cush @RheumNow( View Tweet )
May 13, 2022
PsA,Pod,RNL

RNL 2022: Psoriatic Arthritis Advances

May 11, 2022

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.



This webinar presented exerpts from these lectures along with audience Q & A



  • Psoriatic Arthritis Guidelines Arthur Kavanaugh, MD

  • Drug Targeting in PsA Bruce Kirkham
Read Article
Study of 13 European registries on durability/effect of interleukin-17 (IL-17) inhibition with secukinumab: among 2,017 PsA on secukinumab, retention rates were 86% and 76% at 6 and 12 mos, with 12 mo remission rate of 11% to 16% https://t.co/03sJBSbUy6

Dr. John Cush @RheumNow( View Tweet )

May 04, 2022
TNRPSA,0426

PsA Journal Club - Fecal Transplant & H2H IXE vs ADA

Apr 27, 2022

Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion  about two important studies.

Read Article
TNR,controversies,psa

TNR - Controversies in PsA

Apr 20, 2022

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.



The PsA Expert panelists included:



  • Dr. Dafna Gladman, Toronton

  • Dr. Joseph Merola, Boston

  • Dr. Peter
Read Article
Can IL-22 differentiate between IL-17 & TNF inhibitor #PSA responders? Pilot study 2 cohorts 81 PSA pts showed both biologics worked but somewhat better response in IL-17i Pts w/ low IL- & TNFi responses w/ high IL-22 levels. https://t.co/txyNl2OwTP

Dr. John Cush @RheumNow( View Tweet )

Apr 18, 2022
ICYMI: Males respond better than females? Ixekizumab trials in #PSA - 676 pts in Two Phase 3 RCTs - females had lower response rates than males in all measures (ACR20/50/70; MDA; DAPSA) F had ⬆️HAQ, enthesitis, but ⬇️CRP https://t.co/sjVJZ8uQA3 https://t.co/l7B2ICZWaJ
Dr. John Cush @RheumNow( View Tweet )
Apr 18, 2022
Kids With Psoriasis Maintained with Long Term IL-17A Inhibitorhttps://t.co/CfAjvc9XWg https://t.co/RaD5qqPM3a
Dr. John Cush @RheumNow( View Tweet )
Apr 15, 2022
TNR,PSA,journal,0412

Now Available: TNR - Psoriatic Arthritis Journal Club

Apr 15, 2022

A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.

Read Article
RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

Apr 15, 2022

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 




  1. Downward Effects! Real world data from 22,934 UK #RA pts

Read Article
child.guttate.psoriasis

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

MedPage Today
Apr 14, 2022

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article
Ixekizumab in 1401 #PSA pts w/ 2248 Pt-Yrs exposure showed Serious AE in 134 pts. Most common AEs were nasopharyngitis & URI. Incidence of SAE (≤1.2/100PY), cancer (0.7/100PY), IBD (0.1/00PY), depression (1.6/100PY) were low. #PSAlways https://t.co/YGGj4XCQDM

Dr. John Cush @RheumNow( View Tweet )

Apr 12, 2022
2020 Pt preferences survey- 137 #PsA pts most took TNFi (30%), IL-17i (20%), MTX (10%). From 2018 to 2020 a signif incr in IL-17i & PDE4 inhib. Pts want Rx for damage (80%), ADL (71%), & pain (70%) https://t.co/2dyIuQubh5 https://t.co/sFbtRj0Lbv
Dr. John Cush @RheumNow( View Tweet )
Apr 11, 2022
ICYMI: Review of 5 trials shows ixekizumab with higher rates of complete skin & nail clearance compared H2H against to etanercept, guselkumab, ustekinumab, and adalimumab (Data from IXORA-R, IXORA-S, UNCOVER-2, UNCOVER-3, & SPIRIT-H2H trials https://t.co/t5wrmE3nbK #PsA #PsAlways https://t.co/MQjgktOZWR
Dr. John Cush @RheumNow( View Tweet )
Apr 09, 2022
RheumNow Podcast square

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Apr 08, 2022

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.




  1. CorEvitas Registry study of173 Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted

Read Article
Psoriasis Severe legs sara

Differences in Biologic Persistence in Psoriasis and Psoriatic Arthritis

Mar 29, 2022

Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.

Read Article
Ask Cush Anything! Have a rheumatology question or case for Dr. Cush? Submit it here and we may feature it on an upcoming podcast. https://t.co/KgPIeScthr https://t.co/nk4re9mlcH
Dr. John Cush @RheumNow( View Tweet )
Mar 25, 2022
"Remember bony growth is a feature of the PsA joint and one potential way in which IL17s may target the disease." Dr. B. Kirkham discusses potential synergistic activity of IL17A and TNFi in the SpA joint. #RNL2022 @RheumNow https://t.co/L9uZqoen2w
Dr. Rachel Tate @uptoTate( View Tweet )
Mar 20, 2022
IL-17i - Good Long term safety profile and low malignancy risk Best efficacy for nail psoriasis @RheumNow #RNL2022 https://t.co/8T7wAGJChF
Robert B Chao, MD @doctorRBC( View Tweet )
Mar 20, 2022
#ClinicalPearl Fun fact According to Dr Strober IL17i have BEST effects on nail involvement in #psoriasis. I didn’t know. often need ⬆️dose over time #RNL2022 @RheumNow https://t.co/Y9U9c4M03j
Mar 20, 2022
Run down on IL-17 inhibitors by Dr Strober @BruceStrober #RNL2022 https://t.co/mqXvfJGhij
Dr. John Cush @RheumNow( View Tweet )
Mar 20, 2022
Role of IL17 blockers in creating dysbiosis (expansion of Candida), could that be one of the reasons explaining its effect in SpA and PsA?!! Jose Scher @RheumNow #Rnl2022 https://t.co/AyGgNiDVJ9
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Mar 20, 2022
×